Exobiosphere joins the Cedars Sinai Accelerator+ program with a $1.4M Seed Extension investment

We’re proud to share that Exobiosphere has been selected to join the Cedars-Sinai Accelerator+ program, an internationally recognized initiative supporting health-tech innovators shaping the future of medicine.

As part of our participation, Cedars-Sinai Technology Ventures is making a $1.4 million strategic investment in Exobiosphere to accelerate the development of our Orbital High-Throughput Screener (OHTS), an autonomous and standardized laboratory platform designed to perform thousands of biological tests in microgravity.

“Joining the Cedars-Sinai Accelerator+ is a transformational milestone for Exobiosphere,” said Kyle Acierno, our CEO and Co-Founder. “This partnership allows us to validate our technology with world-class health professionals and accelerate the commercialization of orbital biology at scale.”

Over the year, we’ll work closely with physicians, researchers, and mentors at Cedars-Sinai Medical Center in Los Angeles. This collaboration will help us refine our technology, strengthen our market strategy, and prepare to send biological samples to orbit—advancing drug discovery and disease understanding by leveraging the unique environment of microgravity.

 “Working alongside Cedars-Sinai’s translational ecosystem lets us see where patient care truly meets its limits, and use space as a new frontier to overcome them.,”  said  Dr. Bruno Santos, Co-Founder and Director of R&D .

This milestone follows our recent $2.3 million seed round led by Expansion Ventures and Expon Capital, with additional support from Boryung and Space Data, and our LuxIMPULSE grant from the Luxembourg Space Agency. Together, these achievements strengthen our mission to make orbital biotechnology a core tool for advancing drug discovery and development and improving health on Earth.

Cedars-Sinai Accelerator+